Phaseline

Companies › Beckley Psytech

Beckley Psytech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BPL-003
Intranasal psilocybin
–Phase 2Treatment Resistant DepressionNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05660642BPL-003Phase 2Treatment Resistant DepressionPsychiatryNov 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Draig Therapeutics Kadence Bio HB BioTech Synendos Therapeutics Neuroventi

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.